1
|
Yuan XC, Tao YX. Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin. Biomolecules 2022; 12:biom12101407. [PMID: 36291616 PMCID: PMC9599618 DOI: 10.3390/biom12101407] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2022] [Revised: 09/25/2022] [Accepted: 09/28/2022] [Indexed: 11/16/2022] Open
Abstract
The discovery of melanocortins in 1916 has resulted in more than 100 years of research focused on these peptides. Extensive studies have elucidated well-established functions of melanocortins mediated by cell surface receptors, including MSHR (melanocyte-stimulating hormone receptor) and ACTHR (adrenocorticotropin receptor). Subsequently, three additional melanocortin receptors (MCRs) were identified. Among these five MCRs, MC3R and MC4R are expressed primarily in the central nervous system, and are therefore referred to as the neural MCRs. Since the central melanocortin system plays important roles in regulating energy homeostasis, targeting neural MCRs is emerging as a therapeutic approach for treating metabolic conditions such as obesity and cachexia. Early efforts modifying endogenous ligands resulted in the development of many potent and selective ligands. This review focuses on the ligands for neural MCRs, including classical ligands (MSH and agouti-related peptide), nonclassical ligands (lipocalin 2, β-defensin, small molecules, and pharmacoperones), and clinically approved ligands (ACTH, setmelanotide, bremelanotide, and several repurposed drugs).
Collapse
Affiliation(s)
- Xiao-Chen Yuan
- College of Animal Science and Technology, Anhui Agricultural University, Hefei 230061, China
| | - Ya-Xiong Tao
- Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA
- Correspondence:
| |
Collapse
|
2
|
Salem RM, Abdelrahman AMN, Abd El-Kareem HM, Seif M. DEFB1 gene polymorphisms modify vitiligo extent and response to NB-UVB phototherapy. Dermatol Ther 2021; 34:e14921. [PMID: 33647170 DOI: 10.1111/dth.14921] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2020] [Revised: 02/02/2021] [Accepted: 02/20/2021] [Indexed: 01/05/2023]
Abstract
Human beta defensin-1(hBD-1); an antimicrobial peptide, has immune regulatory effects which may be involved in autoimmunity. The aims were to evaluate the association between defensin beta 1 (DEFB1) (-44 C/G) and (-20 G/A) gene polymorphisms with the risk of vitiligo development, the extent of the disease and the response to NB-UVB treatment in a sample of Egyptian population. 178 active nonsegmental vitiligo patients and 182 control subjects were included in this prospective case control study. Vitiligo extent was evaluated using vitiligo area scoring index (VASI). Gene polymorphisms in all participants were studied by RFLP PCR technique. Patients were treated by three narrowband UVB (NB-UVB) treatment sessions per week. After 12 weeks, the patients were reevaluated clinically to assess the extent of the disease using VASI scoring again and to evaluate the type of repigmentation, if any. AA genotype of DEFB1 (-20G/A) has a protective role against vitiligo development, while (DEFB1 -44 C/G) GG genotype and G allele increase the risk of vitiligo development about two folds. Patients carrying polymorphism in DEFB1 (-20G/A) only showed the lowest VASI scores (14.23 ± 2.77) and the highest percentage of improvement (66.12 ± 18.01%), while patients carrying polymorphism in DEFB1(-44 C/G) only showed the highest baseline VASI scores (38.87 ± 6.7) and the lowest therapeutic response (23.79 ± 19.42%) among all patients groups. Different DEFB1 gene polymorphisms may modify the risk of vitiligo development, the disease extent and the response to NB-UVB phototherapy.
Collapse
Affiliation(s)
- Rehab Mohammed Salem
- Faculty of Medicine, Department of Dermatology and Andrology, Benha University, Benha, Egypt
| | | | | | - Marwa Seif
- Faculty of Medicine, Department of Microbiology and Immunology, Benha University, Egypt
| |
Collapse
|
3
|
Reynaud S, Ciolek J, Degueldre M, Saez NJ, Sequeira AF, Duhoo Y, Brás JLA, Meudal H, Cabo Díez M, Fernández Pedrosa V, Verdenaud M, Boeri J, Pereira Ramos O, Ducancel F, Vanden Driessche M, Fourmy R, Violette A, Upert G, Mourier G, Beck-Sickinger AG, Mörl K, Landon C, Fontes CMGA, Miñambres Herráiz R, Rodríguez de la Vega RC, Peigneur S, Tytgat J, Quinton L, De Pauw E, Vincentelli R, Servent D, Gilles N. A Venomics Approach Coupled to High-Throughput Toxin Production Strategies Identifies the First Venom-Derived Melanocortin Receptor Agonists. J Med Chem 2020; 63:8250-8264. [PMID: 32602722 DOI: 10.1021/acs.jmedchem.0c00485] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Animal venoms are rich in hundreds of toxins with extraordinary biological activities. Their exploitation is difficult due to their complexity and the small quantities of venom available from most venomous species. We developed a Venomics approach combining transcriptomic and proteomic characterization of 191 species and identified 20,206 venom toxin sequences. Two complementary production strategies based on solid-phase synthesis and recombinant expression in Escherichia coli generated a physical bank of 3597 toxins. Screened on hMC4R, this bank gave an incredible hit rate of 8%. Here, we focus on two novel toxins: N-TRTX-Preg1a, exhibiting an inhibitory cystine knot (ICK) motif, and N-BUTX-Ptr1a, a short scorpion-CSαβ structure. Neither N-TRTX-Preg1a nor N-BUTX-Ptr1a affects ion channels, the known targets of their toxin scaffolds, but binds to four melanocortin receptors with low micromolar affinities and activates the hMC1R/Gs pathway. Phylogenetically, these two toxins form new groups within their respective families and represent novel hMC1R agonists, structurally unrelated to the natural agonists.
Collapse
Affiliation(s)
- Steve Reynaud
- Université Paris-Sud, 15 Rue Georges Clemenceau, Orsay 91405 France.,Université Paris Saclay, CEA, Département Médicaments et Technologies pour la Santé, SIMoS, Gif-sur-Yvette 91191 France
| | - Justyna Ciolek
- Université Paris Saclay, CEA, Département Médicaments et Technologies pour la Santé, SIMoS, Gif-sur-Yvette 91191 France
| | - Michel Degueldre
- Mass Spectrometry Laboratory, Université de Liège, Allée du six Aout 11, Quartier Agora, Liege 4000 Belgium.,Department of Analytical Science Biologicals, UCB, Chemin du Foriest, Braine L'Alleud 1420 Belgium
| | - Natalie J Saez
- Centre National de la Recherche Scientifique, Architecture et Fonction des Macromolécules Biologiques, Campus de Luminy, Marseille 13288 France.,Institute for Molecular Bioscience, The University of Queensland, St Lucia 4072, QLD, Australia
| | - Ana Filipa Sequeira
- Universidade de Lisboa, CIISA - Faculdade de Medicina Veterinária, Avenida da Universidade Técnica, Lisboa 1300-477 Portugal.,NZYTech Lda, Genes & Enzymes, Estrada do Paço do Lumiar, Campus do Lumiar, Edifício E - R/C, Lisboa 1649-038 Portugal
| | - Yoan Duhoo
- Centre National de la Recherche Scientifique, Architecture et Fonction des Macromolécules Biologiques, Campus de Luminy, Marseille 13288 France.,Institute for Molecular Bioscience, The University of Queensland, St Lucia 4072, QLD, Australia
| | - Joana L A Brás
- Universidade de Lisboa, CIISA - Faculdade de Medicina Veterinária, Avenida da Universidade Técnica, Lisboa 1300-477 Portugal.,NZYTech Lda, Genes & Enzymes, Estrada do Paço do Lumiar, Campus do Lumiar, Edifício E - R/C, Lisboa 1649-038 Portugal
| | - Hervé Meudal
- Centre National de la Recherche Scientifique, Centre de Biophysique Moléculaire, rue Charles Sadron, Orléans 45071 France
| | - Miguel Cabo Díez
- Next-Generation Sequencing Laboratory, Sistemas Genómicos Ltd., Ronda de Guglielmo Marconi, 6, Paterna 46980 Spain
| | - Victoria Fernández Pedrosa
- Next-Generation Sequencing Laboratory, Sistemas Genómicos Ltd., Ronda de Guglielmo Marconi, 6, Paterna 46980 Spain
| | - Marion Verdenaud
- Université Paris Saclay, CEA, Département Médicaments et Technologies pour la Santé, SIMoS, Gif-sur-Yvette 91191 France
| | - Julia Boeri
- Université Paris Saclay, CEA, Département Médicaments et Technologies pour la Santé, SIMoS, Gif-sur-Yvette 91191 France
| | - Oscar Pereira Ramos
- Université Paris Saclay, CEA, Département Médicaments et Technologies pour la Santé, SIMoS, Gif-sur-Yvette 91191 France
| | - Frédéric Ducancel
- Université Paris Saclay, CEA, Département IDMIT, 18 route du Panorama, 92265 Fontenay-aux-Roses, France
| | - Margot Vanden Driessche
- Université Paris Saclay, CEA, Département Médicaments et Technologies pour la Santé, SIMoS, Gif-sur-Yvette 91191 France
| | - Rudy Fourmy
- Alphabiotoxine Laboratory sprl, Barberie 15, Montroeul-au-bois 7911 Belgium
| | - Aude Violette
- Alphabiotoxine Laboratory sprl, Barberie 15, Montroeul-au-bois 7911 Belgium
| | - Grégory Upert
- Université Paris Saclay, CEA, Département Médicaments et Technologies pour la Santé, SIMoS, Gif-sur-Yvette 91191 France
| | - Gilles Mourier
- Université Paris Saclay, CEA, Département Médicaments et Technologies pour la Santé, SIMoS, Gif-sur-Yvette 91191 France
| | | | - Karin Mörl
- Institute of Biochemistry, Universitat Leipzig, Leipzig 04103 Germany
| | - Céline Landon
- Centre National de la Recherche Scientifique, Centre de Biophysique Moléculaire, rue Charles Sadron, Orléans 45071 France
| | - Carlos M G A Fontes
- Universidade de Lisboa, CIISA - Faculdade de Medicina Veterinária, Avenida da Universidade Técnica, Lisboa 1300-477 Portugal.,NZYTech Lda, Genes & Enzymes, Estrada do Paço do Lumiar, Campus do Lumiar, Edifício E - R/C, Lisboa 1649-038 Portugal
| | - Rebeca Miñambres Herráiz
- Next-Generation Sequencing Laboratory, Sistemas Genómicos Ltd., Ronda de Guglielmo Marconi, 6, Paterna 46980 Spain
| | | | - Steve Peigneur
- Toxicology and Pharmacology, University of Leuven (KU Leuven), Herestraat 49, Leuven 3000 Belgium
| | - Jan Tytgat
- Toxicology and Pharmacology, University of Leuven (KU Leuven), Herestraat 49, Leuven 3000 Belgium
| | - Loïc Quinton
- Mass Spectrometry Laboratory, Université de Liège, Allée du six Aout 11, Quartier Agora, Liege 4000 Belgium
| | - Edwin De Pauw
- Mass Spectrometry Laboratory, Université de Liège, Allée du six Aout 11, Quartier Agora, Liege 4000 Belgium
| | - Renaud Vincentelli
- Centre National de la Recherche Scientifique, Architecture et Fonction des Macromolécules Biologiques, Campus de Luminy, Marseille 13288 France
| | - Denis Servent
- Université Paris Saclay, CEA, Département Médicaments et Technologies pour la Santé, SIMoS, Gif-sur-Yvette 91191 France
| | - Nicolas Gilles
- Université Paris Saclay, CEA, Département Médicaments et Technologies pour la Santé, SIMoS, Gif-sur-Yvette 91191 France
| |
Collapse
|
4
|
Álvarez ÁH, Martínez Velázquez M, Prado Montes de Oca E. Human β-defensin 1 update: Potential clinical applications of the restless warrior. Int J Biochem Cell Biol 2018; 104:133-137. [PMID: 30236992 DOI: 10.1016/j.biocel.2018.09.007] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2018] [Revised: 08/15/2018] [Accepted: 09/15/2018] [Indexed: 01/06/2023]
Abstract
Human β-defensin 1 (hBD-1) is a multifaceted antimicrobial peptide being a tumour suppressor and, depending on call of duty, capable of inducing self-nets and neutrophil extracellular traps (NETs) to capture and/or kill bacteria, participates in inflammatory responses in chronic diseases including hBD-3 upregulation and also capable of up/downregulation in the presence of certain species of Lactobacillus sp. Thus, is regulated by host microbiota. Alleles, genotypes and/or altered gene expression of its coding gene, DEFB1, have been associated with several human diseases/conditions ranging from metabolic/chronic (e.g. cancer), infectious (e.g. tuberculosis, HIV/AIDS), inflammatory (gastrointestinal diseases), male infertility and more recently, neurologic (e.g. depression and Alzheimer) and autoimmune diseases (e.g. vitiligo and systemic lupus erythematosus). The present update focuses on novel DEFB1/hBD-1 properties and biomarker features, its biological function and the pharmaceutical potential uses of antimicrobial peptide elicitors (APEs) or the engineered peptide in the treatment of hBD-1-related human diseases.
Collapse
Affiliation(s)
- Ángel H Álvarez
- Personalized Medicine National Laboratory (LAMPER), Medical and Pharmaceutical Biotechnology Unit, Research Center of Technology and Design Assistance of Jalisco State (CIATEJ), National Council of Science and Technology (CONACYT), Av. Normalistas 800, Col. Colinas de la Normal, Guadalajara, Mexico
| | - Moisés Martínez Velázquez
- Personalized Medicine National Laboratory (LAMPER), Medical and Pharmaceutical Biotechnology Unit, Research Center of Technology and Design Assistance of Jalisco State (CIATEJ), National Council of Science and Technology (CONACYT), Av. Normalistas 800, Col. Colinas de la Normal, Guadalajara, Mexico
| | - Ernesto Prado Montes de Oca
- Personalized Medicine National Laboratory (LAMPER), Medical and Pharmaceutical Biotechnology Unit, Research Center of Technology and Design Assistance of Jalisco State (CIATEJ), National Council of Science and Technology (CONACYT), Av. Normalistas 800, Col. Colinas de la Normal, Guadalajara, Mexico.
| |
Collapse
|